XENP9523
/ Xencor
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 21, 2012
Boehringer Ingelheim and Xencor enter a collaboration agreement for the development, manufacture, and supply of biosuperior monoclonal antibodies
(Boehringer Ingelheim)
- Xencor & Boehringer Ingelheim announced a collaboration agreement for certain Xencor biosuperior monoclonal antibodies; Xencor’s lead biosuperior compound is an anti-TNF antibody engineered using the company’s proprietary Xtend™ antibody engineering technology for increasing antibody half-life; Xencor expects to initiate a P1 trial in 2013 potentially resulting in key human pharmacokinetic data validating Xtend technology
Anticipated P1 trial initiation • Collaboration agreement • Immunology • Rheumatoid Arthritis
1 to 1
Of
1
Go to page
1